Y. Ishkinin, R. Raimbekov, K. Datbayev, A. Goncharova, R. Akhunova, A. Omarova, S. Ossikbayeva, F. Khozhamkul, M. Omirzaq, O. Seitov, Z. Khudaibergenov, N. Omarbayeva
{"title":"2019冠状病毒病期间加速高科技放疗","authors":"Y. Ishkinin, R. Raimbekov, K. Datbayev, A. Goncharova, R. Akhunova, A. Omarova, S. Ossikbayeva, F. Khozhamkul, M. Omirzaq, O. Seitov, Z. Khudaibergenov, N. Omarbayeva","doi":"10.52532/2521-6414-2023-1-67-10-13","DOIUrl":null,"url":null,"abstract":"Relevance: COVID-19 impacts the course of cancer depending on the status and volume of cancer patient vaccination against \nCOVID-19. \nThe study aimed to assess the impact of accelerated high-tech radiation therapy on the course of the oncological process, depending on the status and volume of COVID-19 vaccinations. \nMethods: This quantitative and qualitative prospective randomized controlled scientific study was conducted as part of the implementation of the scientific project, “Innovative approach to managing patients with cancer in the context of the COVID pandemic-19,” \nReg. No. AP13068657. The study involved 221 cancer patients. \nResults: COVID-19 was diagnosed in 54/221 (24.4%) of the study participants, 24 (22.4%) in the standard radiotherapy group, and \n30 (26.3%) in the experimental radiotherapy group. 49/221 (22.2%) of the participants were vaccinated. COVID-19 was detected in \none breast cancer patient in the experimental group (1.5%) two months after vaccination and two patients with prostate cancer (2.4%) \nfour months after vaccination. Relapse-free survival was registered in 59 (85.5%) breast cancer patients in the standard group and \n58 (85.3%) in the experimental group. The overall survival of breast cancer patients was 69 (100.0%) in the standard group and 68 \n(97.0%) in the experimental group. Relapse-free survival was registered in 32 (84.2%) prostate cancer patients in the standard group \nand 41 (89.1%) patients in the experimental group. The overall survival among prostate cancer patients was 34 (89.5%) in the standard \ngroup and 45 (97.8%) in the experimental group. The deaths were not related to COVID-19. The average treatment duration for breast \ncancer was less by 12.9 days, with prostate cancer– by 18.2 days. \nConclusion: In Kazakhstan, 4.8% of cancer patients with COVID-19 died in 2020-2021. The use of accelerated high-tech radiotherapy is justified in the context of the COVID-19 pandemic. Vaccination can prevent COVID-19 development in cancer patients","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ACCELERATED HIGH-TECH RADIOTHERAPY DURING \\nTHE COVID-19\",\"authors\":\"Y. Ishkinin, R. Raimbekov, K. Datbayev, A. Goncharova, R. Akhunova, A. Omarova, S. Ossikbayeva, F. Khozhamkul, M. Omirzaq, O. Seitov, Z. Khudaibergenov, N. Omarbayeva\",\"doi\":\"10.52532/2521-6414-2023-1-67-10-13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Relevance: COVID-19 impacts the course of cancer depending on the status and volume of cancer patient vaccination against \\nCOVID-19. \\nThe study aimed to assess the impact of accelerated high-tech radiation therapy on the course of the oncological process, depending on the status and volume of COVID-19 vaccinations. \\nMethods: This quantitative and qualitative prospective randomized controlled scientific study was conducted as part of the implementation of the scientific project, “Innovative approach to managing patients with cancer in the context of the COVID pandemic-19,” \\nReg. No. AP13068657. The study involved 221 cancer patients. \\nResults: COVID-19 was diagnosed in 54/221 (24.4%) of the study participants, 24 (22.4%) in the standard radiotherapy group, and \\n30 (26.3%) in the experimental radiotherapy group. 49/221 (22.2%) of the participants were vaccinated. COVID-19 was detected in \\none breast cancer patient in the experimental group (1.5%) two months after vaccination and two patients with prostate cancer (2.4%) \\nfour months after vaccination. Relapse-free survival was registered in 59 (85.5%) breast cancer patients in the standard group and \\n58 (85.3%) in the experimental group. The overall survival of breast cancer patients was 69 (100.0%) in the standard group and 68 \\n(97.0%) in the experimental group. Relapse-free survival was registered in 32 (84.2%) prostate cancer patients in the standard group \\nand 41 (89.1%) patients in the experimental group. The overall survival among prostate cancer patients was 34 (89.5%) in the standard \\ngroup and 45 (97.8%) in the experimental group. The deaths were not related to COVID-19. The average treatment duration for breast \\ncancer was less by 12.9 days, with prostate cancer– by 18.2 days. \\nConclusion: In Kazakhstan, 4.8% of cancer patients with COVID-19 died in 2020-2021. The use of accelerated high-tech radiotherapy is justified in the context of the COVID-19 pandemic. Vaccination can prevent COVID-19 development in cancer patients\",\"PeriodicalId\":19480,\"journal\":{\"name\":\"Oncologia i radiologia Kazakhstana\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncologia i radiologia Kazakhstana\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52532/2521-6414-2023-1-67-10-13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologia i radiologia Kazakhstana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52532/2521-6414-2023-1-67-10-13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
ACCELERATED HIGH-TECH RADIOTHERAPY DURING
THE COVID-19
Relevance: COVID-19 impacts the course of cancer depending on the status and volume of cancer patient vaccination against
COVID-19.
The study aimed to assess the impact of accelerated high-tech radiation therapy on the course of the oncological process, depending on the status and volume of COVID-19 vaccinations.
Methods: This quantitative and qualitative prospective randomized controlled scientific study was conducted as part of the implementation of the scientific project, “Innovative approach to managing patients with cancer in the context of the COVID pandemic-19,”
Reg. No. AP13068657. The study involved 221 cancer patients.
Results: COVID-19 was diagnosed in 54/221 (24.4%) of the study participants, 24 (22.4%) in the standard radiotherapy group, and
30 (26.3%) in the experimental radiotherapy group. 49/221 (22.2%) of the participants were vaccinated. COVID-19 was detected in
one breast cancer patient in the experimental group (1.5%) two months after vaccination and two patients with prostate cancer (2.4%)
four months after vaccination. Relapse-free survival was registered in 59 (85.5%) breast cancer patients in the standard group and
58 (85.3%) in the experimental group. The overall survival of breast cancer patients was 69 (100.0%) in the standard group and 68
(97.0%) in the experimental group. Relapse-free survival was registered in 32 (84.2%) prostate cancer patients in the standard group
and 41 (89.1%) patients in the experimental group. The overall survival among prostate cancer patients was 34 (89.5%) in the standard
group and 45 (97.8%) in the experimental group. The deaths were not related to COVID-19. The average treatment duration for breast
cancer was less by 12.9 days, with prostate cancer– by 18.2 days.
Conclusion: In Kazakhstan, 4.8% of cancer patients with COVID-19 died in 2020-2021. The use of accelerated high-tech radiotherapy is justified in the context of the COVID-19 pandemic. Vaccination can prevent COVID-19 development in cancer patients
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
